Clinical Trials Report Highlights Australia’s Competitive Advantages… And Weaknesses
A new report has found that Australia’s clinical trials sector is large. As international competition for clinical trials intensifies, Australian medtech trade group, MTAA, has pledged to work with industry to overcome impediments to conducting trials in the country.
You may also be interested in...
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
Quviviq is to become the first dual orexin receptor antagonist available on the National Health Service. Just over 20,000 people in England could receive treatment with the drug in its first year, says the health technology assessment institute, NICE.
The European Medicines Agency is to recommend whether the marketing authorization for Currax’s weight management drug should be maintained, varied, suspended or revoked.